HC Wainwright Analysts Give HTG Molecular Diagnostics (HTGM) a $6.00 Price Target

HC Wainwright set a $6.00 target price on HTG Molecular Diagnostics (NASDAQ:HTGM) in a research note released on Wednesday, December 27th. The brokerage currently has a buy rating on the medical research company’s stock.

Other equities analysts have also recently issued reports about the company. ValuEngine raised HTG Molecular Diagnostics from a strong sell rating to a sell rating in a research report on Monday, October 23rd. Zacks Investment Research raised HTG Molecular Diagnostics from a hold rating to a buy rating and set a $2.50 price objective on the stock in a research report on Wednesday, November 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of $5.19.

HTG Molecular Diagnostics (NASDAQ HTGM) opened at $3.71 on Wednesday. The stock has a market capitalization of $38.58 and a P/E ratio of -1.45. HTG Molecular Diagnostics has a 12-month low of $1.20 and a 12-month high of $13.25.

An institutional investor recently raised its position in HTG Molecular Diagnostics stock. Vanguard Group Inc. lifted its stake in HTG Molecular Diagnostics Inc (NASDAQ:HTGM) by 38.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 135,234 shares of the medical research company’s stock after purchasing an additional 37,841 shares during the period. Vanguard Group Inc. owned 1.42% of HTG Molecular Diagnostics worth $359,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.15% of the company’s stock.

WARNING: “HC Wainwright Analysts Give HTG Molecular Diagnostics (HTGM) a $6.00 Price Target” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://stocknewstimes.com/2018/01/12/htg-molecular-diagnostics-htgm-given-a-6-00-price-target-by-hc-wainwright-analysts.html.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply